We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+31.73%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$422M
AUM Growth
+$153M
Cap. Flow
+$112M
Cap. Flow %
26.56%
Top 10 Hldgs %
59.67%
Holding
84
New
36
Increased
11
Reduced
13
Closed
17

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$9.63M
2
TSRO
TESARO, Inc.
TSRO
+$5.7M
3
VIVE
VIVEVE MED INC
VIVE
+$5.55M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.36M
5
ZGNX
Zogenix, Inc.
ZGNX
+$4.43M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$21.3M
2
AKBA icon
Akebia Therapeutics
AKBA
+$7.28M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$5.35M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$4.98M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$4.47M

Sector Composition

Rank Sector Weight
1 Healthcare 60.69%
2 Technology 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$4.74M 1.12%
+437,113
New +$4.43M
VRAY
27
DELISTED
ViewRay, Inc.
VRAY
$4.64M 1.1%
+601,073
New +$3.28M
AVXS
28
DELISTED
AveXis, Inc. Common Stock
AVXS
$4.26M 1.01%
+56,000
New +$3.47M
ANAB icon
29
AnaptysBio
ANAB
$1.59B
$4.14M 0.98%
+165,690
New +$3.86M
NDRM
30
CALL
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.98M 0.94%
+150,000
New +$3.72M
MDCO
31
DELISTED
Medicines Co
MDCO
$3.42M 0.81%
+70,000
New +$3.19M
EVH icon
32
Evolent Health
EVH
$353M
$3.35M 0.79%
+150,000
New +$2.88M
NSTG
33
DELISTED
NanoString Technologies, Inc.
NSTG
$3.28M 0.78%
+164,932
New +$3.14M
IMMU
34
DELISTED
Immunomedics Inc
IMMU
$3.25M 0.77%
503,000
-4,197,000
-89% -$21.3M
AUPH icon
35
Aurinia Pharmaceuticals
AUPH
$1.87B
$2.94M 0.7%
400,000
-600,000
-60% -$2.77M
BCRX icon
36
CALL
BioCryst Pharmaceuticals
BCRX
$2.24B
$2.73M 0.65%
325,000
+226,000
+228% +$1.57M
CLVS
37
DELISTED
Clovis Oncology, Inc.
CLVS
$2.57M 0.61%
+40,361
New +$2.45M
CRBP icon
38
PUT
Corbus Pharmaceuticals
CRBP
$165M
$2.39M 0.57%
+9,667
New +$2.37M
MRVL icon
39
CALL
Marvell Technology
MRVL
$174B
$2.25M 0.53%
+147,500
New +$2.27M
EPIX
40
DELISTED
ESSA Pharma
EPIX
$1.88M 0.44%
30,265
– –
NKTR icon
41
PUT
Nektar Therapeutics
NKTR
$2.38B
$1.8M 0.43%
+5,107
New +$1.15M
EVH icon
42
CALL
Evolent Health
EVH
$353M
$1.78M 0.42%
+80,000
New +$1.54M
SAGE
43
PUT
DELISTED
Sage Therapeutics
SAGE
$1.42M 0.34%
+20,000
New +$1.17M
PGNX
44
PUT
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.42M 0.34%
+150,000
New +$1.5M
CLSD
45
DELISTED
Clearside Biomedical
CLSD
$1.39M 0.33%
11,667
– –
ALIM
46
DELISTED
Alimera Sciences
ALIM
$1.36M 0.32%
64,955
– –
ELOS
47
DELISTED
Syneron Medical Ltd
ELOS
$1.29M 0.31%
+122,400
New +$1.18M
VCYT icon
48
CALL
Veracyte
VCYT
$3.61B
$1.19M 0.28%
130,000
-245,000
-65% -$2M
ZGNX
49
PUT
DELISTED
Zogenix, Inc.
ZGNX
$1.08M 0.26%
+100,000
New +$1.01M
ARRY
50
CALL
DELISTED
Array Biopharma Inc
ARRY
$1.08M 0.26%
+120,500
New +$1.28M
1
2
3 4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2017 Portfolio in Review

As of Q1 2017, Acuta Capital Partners held 84 positions worth $422M, up 57% from $269M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Acuta Capital Partners deployed $112M of net new capital in Q1 2017, opening 36 new positions and adding to 11 existing holdings. Its largest new stake was TESARO, Inc.: 35,000 shares worth $5.38M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 77% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $21.3M trimmed.

  • Acuta Capital Partners's largest Q1 2017 buy was TESARO, Inc.: 35,000 shares worth $5.38M.
  • Acuta Capital Partners added most to Acadia Pharmaceuticals in Q1 2017, an estimated $9.63M increase.
  • Acuta Capital Partners's biggest Q1 2017 reduction was Immunomedics Inc, cutting an estimated $21.3M.
  • Acuta Capital Partners fully exited Akebia Therapeutics in Q1 2017, selling an estimated $7.28M.
  • Acuta Capital Partners's ten largest holdings make up 60% of its $422M portfolio in Q1 2017.
  • Acuta Capital Partners opened 36 new positions and closed 17 in Q1 2017.
  • Acuta Capital Partners's portfolio value rose 57% quarter-over-quarter to $422M.

Based on Acuta Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.